Perinatal Outcomes in Pregnancies Managed with Antenatal Insulin Glargine

 

 Buy Article Permissions and Reprints

ABSTRACT

We compared perinatal outcomes in pregnancies in which insulin glargine was used in the management of patients with pregnancies in which standard insulin therapy was used at a single institution. A retrospective analysis of 114 pregnant patients with diabetes (pregestational or gestational) managed at a single center between January 2004 and August 2006 was undertaken. Sixty-five patients managed with insulin glargine were compared with 49 patients managed with neutral protamine Hagedorn (NPH) insulin. Both groups were also treated with short-acting insulin (either regular, lispro, or aspart insulin). Maternal age, parity, prepregnancy weight, body mass index, duration of diabetes, hemoglobin A_1C (at entry and final recorded) and gestational age at entry were similar for each group (glargine and NPH). Thirty patients had gestational diabetes (18 glargine and 12 NPH); there were no differences in numbers of patients in higher-order White's classification between the two groups. Cesarean section for obstetric reasons included labor abnormalities, malpresentation, fetal distress, and suspected macrosomia. There were no differences in gestational age at delivery, birth weight, preeclampsia, or frequency of cesarean section (total or for obstetric reasons). The frequency of shoulder dystocia was higher in the NPH group. Regarding neonatal outcomes, gestational age at delivery, birth weight, Apgar scores, admission to the neonatal intensive care unit, respiratory distress syndrome, hypoglycemia, and congenital anomalies were similar between the two groups. From this retrospective analysis, no adverse maternal or neonatal effects were seen from maternal administration of insulin glargine. A larger multicenter study is needed to confirm these findings. This preliminary report suggests that use of insulin glargine during pregnancy can be considered if maternal metabolic control is suboptimal using the standard split-mix regimen.

REFERENCES

• 1 Masson E A, Patmore J E, Brash P D et al.. Pregnancy outcome in type 1 diabetes mellitus treated with insulin lispro (Humalog).  Diabet Med. 2003;  20 46-50
  CrossrefPubMedGoogle Scholar
• 2 Pettitt D J, Ospina P, Howard C, Zisser H, Jovanovic L. Efficacy, safety, and lack of immunogenicity of insulin aspart compared with regular human insulin for women with gestational diabetes mellitus.  Diabet Med. 2007;  24 1129-1135
  CrossrefPubMedGoogle Scholar
• 3 Mathiesen E R, Kinsley B, Amiel S A on behalf of the Insulin Aspart Pregnancy Study Group et al. Maternal glycemic control and hypoglycemia in type 1 diabetic pregnancy: a randomized trial of insulin aspart versus human insulin in 322 pregnant women.  Diabetes Care. 2007;  30 771-776
  CrossrefPubMedGoogle Scholar
• 4 Wang F, Carabino J M, Vergara C M. Insulin glargine: a systematic review of a long-acting insulin analogue.  Clin Ther. 2003;  25 1541-1575
  CrossrefPubMedGoogle Scholar
• 5 Ratner R E, Hirsch I B, Neifing J L, Garg S K, Mecca T E, Wilson C A. for the US Study Group of Insulin Glargine in Type 1 Diabetes . Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes.  Diabetes Care. 2000;  23 639-643
  CrossrefPubMedGoogle Scholar
• 6 Kurtzhals P, Schäffer L, Sørensen A et al.. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use.  Diabetes. 2000;  49 999-1005
  CrossrefPubMedGoogle Scholar
• 7 American College of Obstetricians and Gynecologists . Clinical guidelines for obstetrician-gynecologists. Gestational diabetes. ACOG Practice Bulletin Number 30, 2001.  Obstet Gynecol. 2001;  98 525-538
  PubMedGoogle Scholar
• 8 American Academy of Pediatrics Subcommittee on Hyperbilirubinemia . Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation.  Pediatrics. 2004;  114 297-316
  CrossrefPubMedGoogle Scholar
• 9 Dailey G, Strange P. Lower severe hypoglycemia risk: insulin glargine versus NPH insulin in type 2 diabetes.  Am J Manag Care. 2008;  14 25-30
  PubMedGoogle Scholar
• 10 Horvath K, Jeitler K, Berghold A et al.. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus.  Cochrane Database Syst Rev. 2007;  18 CD005613
  PubMedGoogle Scholar
• 11 Duckworth W, Davis S N. Comparison of insulin glargine and NPH insulin in the treatment of type 2 diabetes: a review of clinical studies.  J Diabetes Complications. 2007;  21 196-204
  CrossrefPubMedGoogle Scholar
• 12 Gallen I W, Jaap A, Roland J M, Cirayath H H. Survey of glargine use in 115 pregnant women with type 1 diabetes.  Diabet Med. 2008;  25 165-169 , Epub 2008 Jan 19
  CrossrefPubMedGoogle Scholar
• 13 Price N, Bartlett C, Gillmer M. Use of insulin glargine during pregnancy: a case-control pilot study.  BJOG. 2007;  114 453-457 , Epub 2007 Jan 25
  PubMedGoogle Scholar
• 14 Pöyhönen-Alho M, Rönnemaa T, Saltevo J, Ekblad U, Kaaja R J. Use of insulin glargine during pregnancy.  Acta Obstet Gynecol Scand. Aug 29 2007;  1-4
  PubMedGoogle Scholar
• 15 Cordero L, Treuer S H, Landon M B, Gabbe S G. Management of infants of diabetic mothers.  Arch Pediatr Adolesc Med. 1998;  152 249-254
  PubMedGoogle Scholar

Robert S EgermanM.D. 

Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of Tennessee Health Science Center

Memphis, 853 Jefferson Avenue Suite E102, Memphis, TN 38163-0001

Email: regerman@utmem.edu